OBJECTIVE: The Veterans Aging Cohort Study (VACS) Index is predictive of mortality and combines age, traditional HIV biomarkers (HIV-1 plasma RNA and current CD4 count), and non-HIV biomarkers (indicators of renal and liver function, anemia, and hepatitis C coinfection). We examined the association between the VACS Index and HIV-associated neurocognitive impairment (NCI). DESIGN AND METHODS: Participants included 601 HIV-infected adults enrolled in cohort studies at the University of California, San Diego, HIV Neurobehavioral Research Program (ages: 18-76 years; 88% male; 63% white; median current CD4 = 364 cells/mm; 63% on antiretroviral therapy; AIDS = 64%). Biomarkers used in calculating the VACS Index were measured in prospectively collected blood samples using conventional laboratory methods. NCI was defined using global and seven domain deficit scores. RESULTS: Higher VACS Index scores were associated with concurrent risk for global NCI [P < 0.001; odds ratio = 1.21, confidence interval (CI): 1.12 to 1.32], even when adjusting for psychiatric comorbidities. This relation was statistically significant for most cognitive domains in adjusted models. Furthermore, the VACS Index predicted concurrent NCI beyond nadir CD4 and estimated duration of infection. Older age, lower hemoglobin, and lower CD4 counts were the VACS components most strongly linked to NCI. CONCLUSIONS: The findings extend previous research on the potential usefulness of the VACS Index in predicting HIV-associated outcomes to include NCI. Although the effect size was relatively small, our findings suggest that demographic information, HIV-disease factors, and common comorbidities might each play important roles in the clinical manifestation of cognitive impairment among HIV-infected individuals. Additional research is needed to determine if a more sensitive and specific index can be developed.
OBJECTIVE: The Veterans Aging Cohort Study (VACS) Index is predictive of mortality and combines age, traditional HIV biomarkers (HIV-1 plasma RNA and current CD4 count), and non-HIV biomarkers (indicators of renal and liver function, anemia, and hepatitis C coinfection). We examined the association between the VACS Index and HIV-associated neurocognitive impairment (NCI). DESIGN AND METHODS: Participants included 601 HIV-infected adults enrolled in cohort studies at the University of California, San Diego, HIV Neurobehavioral Research Program (ages: 18-76 years; 88% male; 63% white; median current CD4 = 364 cells/mm; 63% on antiretroviral therapy; AIDS = 64%). Biomarkers used in calculating the VACS Index were measured in prospectively collected blood samples using conventional laboratory methods. NCI was defined using global and seven domain deficit scores. RESULTS: Higher VACS Index scores were associated with concurrent risk for global NCI [P < 0.001; odds ratio = 1.21, confidence interval (CI): 1.12 to 1.32], even when adjusting for psychiatric comorbidities. This relation was statistically significant for most cognitive domains in adjusted models. Furthermore, the VACS Index predicted concurrent NCI beyond nadir CD4 and estimated duration of infection. Older age, lower hemoglobin, and lower CD4 counts were the VACS components most strongly linked to NCI. CONCLUSIONS: The findings extend previous research on the potential usefulness of the VACS Index in predicting HIV-associated outcomes to include NCI. Although the effect size was relatively small, our findings suggest that demographic information, HIV-disease factors, and common comorbidities might each play important roles in the clinical manifestation of cognitive impairment among HIV-infected individuals. Additional research is needed to determine if a more sensitive and specific index can be developed.
Authors: N Sacktor; R L Skolasky; P M Tarwater; J C McArthur; O A Selnes; J Becker; B Cohen; B Visscher; E N Miller Journal: Neurology Date: 2003-08-26 Impact factor: 9.910
Authors: Y Stern; M P McDermott; S Albert; D Palumbo; O A Selnes; J McArthur; N Sacktor; G Schifitto; K Kieburtz; L Epstein; K S Marder Journal: Arch Neurol Date: 2001-03
Authors: V Tozzi; P Balestra; R Murri; S Galgani; R Bellagamba; P Narciso; A Antinori; M Giulianelli; G Tosi; M Fantoni; A Sampaolesi; P Noto; G Ippolito; A W Wu Journal: Int J STD AIDS Date: 2004-04 Impact factor: 1.359
Authors: Charles H Hinkin; David J Hardy; Karen I Mason; Steven A Castellon; Ramani S Durvasula; Mona N Lam; Marta Stefaniak Journal: AIDS Date: 2004-01-01 Impact factor: 4.177
Authors: Robert K Heaton; Thomas D Marcotte; Monica Rivera Mindt; Joseph Sadek; David J Moore; Heather Bentley; J Allen McCutchan; Carla Reicks; Igor Grant Journal: J Int Neuropsychol Soc Date: 2004-05 Impact factor: 2.892
Authors: Julie D Rippeth; Robert K Heaton; Catherine L Carey; Thomas D Marcotte; David J Moore; Raul Gonzalez; Tanya Wolfson; Igor Grant Journal: J Int Neuropsychol Soc Date: 2004-01 Impact factor: 2.892
Authors: Christopher T Rentsch; David A Fiellin; Kendall J Bryant; Amy C Justice; Janet P Tate Journal: Alcohol Clin Exp Res Date: 2019-02-03 Impact factor: 3.455
Authors: Kathleen M Akgün; Janet P Tate; Kristina Crothers; Stephen Crystal; David A Leaf; Julie Womack; Todd T Brown; Amy C Justice; Krisann K Oursler Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: Anna L Hotton; Kathleen M Weber; Ronald C Hershow; Kathryn Anastos; Peter Bacchetti; Elizabeth T Golub; Deborah Gustafson; Alexandra M Levine; Mary Young; Mardge H Cohen Journal: J Acquir Immune Defic Syndr Date: 2017-06-01 Impact factor: 3.731
Authors: Matteo Vassallo; R Fabre; J Durant; C Lebrun-Frenay; H Joly; M Ticchioni; F DeSalvador; A Harvey-Langton; B Dunais; M Laffon; J Cottalorda; P Dellamonica; C Pradier Journal: J Neurovirol Date: 2016-11-04 Impact factor: 2.643
Authors: Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Yih-Ing Hser; Gregory M Lucas; Amy C Justice; Janet P Tate Journal: Drug Alcohol Depend Date: 2019-09-04 Impact factor: 4.492
Authors: María J Marquine; Jessica L Montoya; Anya Umlauf; Pariya L Fazeli; Ben Gouaux; Robert K Heaton; Ronald J Ellis; Scott L Letendre; Igor Grant; David J Moore Journal: Clin Infect Dis Date: 2016-05-19 Impact factor: 9.079